Biodesix Prices $72M IPO
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
Becton Dickinson Wins $6M Contract to Combat Antimicrobial Resistance
BD will supply its diagnostics and informatics products as part of the contract with Fleming Fund to take on AMR in Asia and sub-Saharan Africa.
Biodesix, MRM Proteomics Partner on Lung Cancer Assays
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
MRM Proteomics Partnering With Exactis on Proteomic Test for Cancer Immunotherapy
The test will be based on MRM Proteomics' immunoMALDI approach, which uses antibody enrichment of target proteins followed by analysis via MALDI mass spec.
The assay combines antibody enrichment with MALDI mass spec to measure isoforms of transferrin, a protein biomarker used to track alcohol consumption.